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Benign anastomotic stricture of the rectum complicated by metal stent
insertion: Salvage by placement of a biodegradable polydioxanone stent
Damian Mullan,1 Sarah T. O’Dwyer,2 Hans-Ulrich Laasch1,*
a b s t r a c t
After radical treatment for a rectal carcinoma, a male patient developed an anastomotic stricture that was resistant to balloon dilatation. Inappropriate
placement of an uncovered metal stent had failed to cross the stenosis. Attempts to remove the stent were unsuccessful and a self-expanding poly-
dioxanone esophageal stent was implanted. The procedure resulted in long-term patency and allowed the defunctioning ileostomy to be reversed. This
case of a challenging anastomotic stricture supports other very limited experiences indicating that polydioxanone stents in the colon have the same
pattern of degradation as elsewhere in the gastrointestinal tract. These stents can re-establish permanent patency, even in a hostile territory and in
patients for whom previous dilatation has failed.
Copyright  2013, Society of Gastrointestinal Intervention. Published by Elsevier.
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Benign strictures of the gastrointestinal (GI) tract can severely
impair a patient’s quality of life and may present a formidable
management challenge. Stenting intuitively offers a better chance
of remodeling the stricture, compared to the short-term disruption
achieved by pneumatic dilatation. Permanent insertion of a metal
stent is contraindicated, although temporary stenting with fully
covered removable stents can be performed.1 In Europe, a single
type of biodegradable stentdthe SX-Ella biodegradable (BD) stent
(Ella-CS, Hradec Kralove, Czech Republic)dis commercially avail-
able (Fig. 1). However, it is only licensed for benign esophageal
strictures. They have been used off-label successfully for the tem-
porary treatment of benign and malignant strictures throughout
the GI tract,2–7 and they show promising results in treating anas-
tomotic rectal strictures.8,9
SX-Ella BD stents are braided from a polydioxanone mono-
ﬁlament in a conventional fashion. The stents are radiolucent with
seven radiopaque markers. SX-Ella BD stents need to be loaded by
hand into the delivery system prior to use (at which point signiﬁ-
cant elongation occurs, as seen with braided metal stents). The
stents are available in diameters of 18–25 mm and lengths of
60–135 mm (Fig. 1). The 28 Fr delivery system is designed for use in
the esophagus and the tortuous access route requires an ultra-stiff
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force exerted by the Wallﬂex nitinol stent (Boston-Scientiﬁc,
St. Albans, UK) (166 g vs. 269 g, respectively); the force of the BD
stent is also reduced in larger sizes. The radial force is maintained
6–8 weeks, after which the stent starts to weaken. Biodegradable
stents begin to disintegrate after 3 months and usually have dis-
appeared after 4 months. This process is accelerated in an acidic
environment. The cost of biodegradable stents and metal stents are
comparable.
Case report
After neoadjuvant radiotherapy and a curative anterior resec-
tion of a T3 rectal tumor, a 53-year-old man developed an anasto-
motic stricture. This was conﬁrmed by endoscopy and a barium
enema (Fig. 2). The stricture prevented reversal of the defunc-
tioning ileostomy.
Balloon dilatation failed to achieve long-term patency. A
Wallﬂex stent (Boston Scientiﬁc, St Albans, UK) was inserted at a
local hospital. Despite the combined use of endoscopic and ﬂuo-
roscopic guidance, the stent was unfortunately deployed below the
stricture because the guide wire had not crossed the lesion (Fig. 3).
Fifteen months after the insertion of the metal stent, the patient
was referred to the supraregional cancer center for the insertion of
a biodegradable stent. An attempt to remove the metal stent byster M20 4 BX, United Kingdom.
vier. Open access under CC BY-NC-ND license.
Fig. 2. Rectal stricture. The barium enema reveals a short, tight anastomotic rectal
stricture (arrow).
Fig. 1. Degradation of the BD stent. (A) A 22 mm  60 mm Ella-BD stent. (B) An 18-mm
demonstration model disintegrating after 18 months of exposure to room air.
Fig. 3. Endoscopic stent insertion. Injection of contrast medium reveals an an
Fig. 4. BD stent insertion. (A) The radiolucent SX-Ella-BD stent is in position across the
stricture prior to deployment. The position is indicated by seven radiopaque markers
(arrowheads). (B). A deployed BD stent after dilatation to 12 mm at the level of the
stricture (arrow). The arrowheads indicate the residual intramucosal nitinol wires.
Gastrointestinal Intervention 2013 2(1), 59–6160endoscopy was only partially successful because an uncovered
stent had been used.
The institutional review board approved the procedure. The
patient provided consent for the off-label use of the BD stent.astomotic stricture (arrow), but the Wallﬂex stent is deployed below it.
Fig. 5. Stent position. Axial computed tomography (bone windows) at the level of the
hip joints shows dense contrast (from the insertion procedure) passing through the
stent, which is surrounded by strands of nitinol wire (arrow).
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roscopic guidance, the stricture was crossed with a straight hy-
drophilic wire (Terumo, Prescot, UK) and a 6 Fr biliary manipulation
catheter (Cook, Hitchin, UK). After the stricture was outlined with
water-soluble contrast medium, a 25 mm  60 mm uncovered
esophageal Ella BD stent was inserted over an ultra-stiff back-up
Meier wire (Boston Scientiﬁc, St. Albans, UK) and deployed without
difﬁculty (Fig. 4A, B). Residual strands of wire from the original
stent were embedded in the rectal mucosa. Limited balloon dila-
tation to 12 mm was performed in consideration of posttreatment
ﬁbrosis and the surrounding nitinol wires.
Computed tomography (CT) scans on the same day showed the
stent in good positionwith 60% stent expansion (Fig. 5). The patient
made an uneventful recovery. His ileostomywas reversed 3months
later. After 4 months, the BD stent had dissolved and the anasto-
mosis allowed the passage of a colonoscope. Eighteen months after
the BD stent insertion, the patient had minor rectal seepage and
occasional spasmodic abdominal pain, but declined any further
assessment or intervention.
Discussion
Biodegradable stents allow temporary stenting without the
need for a removal procedure. These stents achieve symptom
reliefdat least, while in situ. Permanent patency in benign esoph-
ageal strictures may not be achieved, even by repeated stent
insertion.10 However, initial results with short ﬁbrotic strictures
(e.g., surgical anastomoses) are promising. This suggests that
strictures of different etiologies may respond in a different fashion.
BD stents have a lower expansion force than metal stents and
lack the superelastic properties of nitinol. However, no data exist on
the minimum force that is indeed required for sufﬁcient stricture
dilatation. In our patient, we assumed that perirectal ﬁbrosis from
previous radiotherapy and the surrounding remnant of the metal
stent would prevent adequate stent expansion. Limited dilatation
to only 50% of the stent diameter was performed to minimize therisk of perforation. As with metal stents, expansion is a process that
often takes several days. Balloon dilatation should only be per-
formed if a delivery system cannot be passed or if dilatation is
needed in a particularly hostile environment. However, balloon
dilatation can always be performed at a later time if stent expansion
proves clinically insufﬁcient.
A degree of hypertrophic mucosal overgranulation from direct
irritation is common while a BD stent is in place and cases of stent
obstruction have been reported.11,12 However, this is rarely a
problem clinically and, more importantly, it seems reversible after
the stent has dissolved.
In conclusion, the off-label use of BD stents in the colon may be
considered in patients with anastomotic strictures for whom at-
tempts at conventional dilatation have failed. Their application in
other pathologies such as diverticular or ischemic stricture has yet
to be evaluated.Conﬂict of interest
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